Hermann Sorgho

List of Publications by Year
in descending order

41 papers	3,628 citations	331670 21 h-index	265206 42 g-index
42 all docs	42 docs citations	42 times ranked	4798 citing authors

#	Article	IF	Citations
1	Genetic associations with carotid intima-media thickness link to atherosclerosis with sex-specific effects in sub-Saharan Africans. Nature Communications, 2022, 13, 855.	12.8	10
2	Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection. JCI Insight, 2022, 7, .	5.0	6
3	Meta-analysis of sub-Saharan African studies provides insights into genetic architecture of lipid traits. Nature Communications, 2022, 13, 2578.	12.8	18
4	Community perspectives on maternal and child health during nutrition and economic transition in sub-Saharan Africa. Public Health Nutrition, 2021, 24, 3710-3718.	2.2	17
5	Prevalence and socio-demographic correlates of tobacco and alcohol use in four sub-Saharan African countries: a cross-sectional study of middle-aged adults. BMC Public Health, 2021, 21, 1126.	2.9	16
6	In vivo/ex vivo efficacy of artemetherâ€“lumefantrine and artesunateâ€“amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal, 2020, 19, 8.	2.3	17
7	Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Vaccine, 2020, 38, 897-906.	3.8	12
8	â€˜Men are not playing their rolesâ€™, maternal and child nutrition in Nanoro, Burkina Faso. Public Health Nutrition, 2020, 24, 1-11.	2.2	9
9	The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey. BMC Infectious Diseases, 2020, 20, 46.	2.9	15
10	Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso . Drug Design, Development and Therapy, 2020, Volume 14, 1507-1521.	4.3	8
11	Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2019, 19, 821-832.	9.1	45
12	Kidney damage and associated risk factors in rural and urban sub-Saharan Africa (AWI-Gen): a cross-sectional population study. The Lancet Global Health, 2019, 7, e1632-e1643.	6.3	56
13	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nature Communications, 2019, 10, 2174.	12.8	123
14	Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2019, 15, 2386-2398.	3.3	48
15	Novel and Known Gene-Smoking Interactions With cIMT Identified as Potential Drivers for Atherosclerosis Risk in West-African Populations of the AWI-Gen Study. Frontiers in Genetics, 2019, 10, 1354.	2.3	10
16	Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. Human Vaccines and Immunotherapeutics, 2018, 14, 1489-1500.	3.3	14
17	Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections. Nature Communications, 2018, 9, 1381.	12.8	27
18	Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study. Malaria Journal, 2018, 17, 163.	2.3	21

#	Article	IF	Citations
19	Regional and sex-specific variation in BMI distribution in four sub-Saharan African countries: The H3Africa AWI-Gen study. Global Health Action, 2018, 11, 1556561.	1.9	37
20	Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study. Global Health Action, 2018, 11, 1507133.	1.9	82
21	Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children. BMC Medicine, 2018, 16, 197.	5.5	65
22	Modulation of innate immune responses at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC Medicine, 2018, 16, 198.	5.5	24
23	Gender differences in sociodemographic and behavioural factors associated with BMI in an adult population in rural Burkina Faso â€“ an AWI-Gen sub-study. Global Health Action, 2018, 11, 1527557.	1.9	8
24	Diagnosing congenital malaria in a high-transmission setting: clinical relevance and usefulness of P. falciparum HRP2-based testing. Scientific Reports, 2017, 7, 2080.	3.3	24
25	Regional and Sex Differences in the Prevalence and Awareness of Hypertension: An H3Africa AWI-Gen Study Across 6 Sites in Sub-Saharan Africa. Global Heart, 2017, 12, 81.	2.3	105
26	Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLoS ONE, 2016, 11, e0151565.	2.5	37
27	Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. Reproductive Health, 2015, 12, 112.	3.1	20
28	Effectiveness and safety of artemetherâ€“lumefantrine versus artesunateâ€“amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria Journal, 2015, 14, 325.	2.3	22
29	Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan African Medical Journal, 2015, 21, 101.	0.8	11
30	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. New England Journal of Medicine, 2015, 373, 2025-2037.	27.0	332
31	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1450-1458.	9.1	262
32	Effectiveness of artesunateâ€“amodiaquine vs. artemetherâ€“lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a nonâ€inferiority randomised trial. Tropical Medicine and International Health, 2014, 19, 469-475.	2.3	24
33	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
34	The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malaria Journal, 2014, 13, 113.	2.3	19
35	Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal, 2014, 13, 207.	2.3	22
36	Profile: Nanoro Health and Demographic Surveillance System. International Journal of Epidemiology, 2012, 41, 1293-1301.	1.9	79

#	Article	IF	Citations
37	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
38	An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal, 2012, 11, 71.	2.3	74
39	First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine, 2011, 365, 1863-1875.	27.0	773
40	Major reduction of malaria morbidity with combined vitamin A and zinc supplementation in young children in Burkina Faso: a randomized double blind trial. Nutrition Journal, 2008, 7, 7.	3.4	81
41	Serodiagnosis of Schistosoma mansoni infections in an endemic area of Burkina Faso: performance of several immunological tests with different parasite antigens. Acta Tropica, 2005, 93, 169-180.	2.0	37